A uniform dose of aspirin across patients with different body types was not linked with a corresponding benefit, according to a new study published in The Lancet.
Researchers for the study looked at individual patient data to analyze the effects that bodyweight and height had on low dose (≤100 mg) and higher-dose (300–325 mg or ≥500 mg) aspirin across 10 clinical trials of aspiring in primary prevention of cardiovascular events. The analysis included data on 117,279 participants, who were stratified by age, sex, and vascular risk factors. They also assessed whether height or weight was linked with the 20-year colorectal cancer risk for any in-trial cancers in the included studies.
According to the results, the beneficial effects of low-dose aspirin lessened as weight increased (P=0.0072 for interaction), showing benefit in patients weighing between 50 kg and 69 kg (HR=0.75; 95% CI, 0.65 to 0.85), but not in participants weighing 70 kg or more (HR=0.95; 95% CI, 0.86 to 1.04). Conversely, fatality from a first cardiovascular event was increased in patients weighting at least 70 kg (OR=1.33; 95% CI, 1.08 to 1.64; P=0.0082). Higher-dose aspirin was associated with reduced cardiovascular events in higher-weight individuals (P=0.017). Additionally, aspirin-medicated reductions in long-term colorectal cancer risk were observed to be weight-dependent (P=0.038).
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.